Product Name :
Esomeprazole (magnesium salt)
Description:
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
CAS:
1198768-91-0
Molecular Weight:
713.12
Formula:
C34H36MgN6O6S2
Chemical Name:
magnesium(2+) 5-methoxy-2-[(R)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide 5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide
Smiles :
[Mg+2].CC1=CN=C(C[S@](=O)C2[N-]C3=CC=C(C=C3N=2)OC)C(C)=C1OC.CC1=CN=C(C[S@@](=O)C2[N-]C3=CC=C(C=C3N=2)OC)C(C)=C1OC
InChiKey:
KWORUUGOSLYAGD-FHPCUDFMSA-N
InChi :
InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2/t2*24-;/m10./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Umifenovir} web|{Umifenovir} SARS-CoV|{Umifenovir} Purity & Documentation|{Umifenovir} References|{Umifenovir} custom synthesis|{Umifenovir} Cancer}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.|Product information|CAS Number: 1198768-91-0|Molecular Weight: 713.12|Formula: C34H36MgN6O6S2|Synonym:|Nexium|Chemical Name: magnesium(2+) 5-methoxy-2-[(R)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide 5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide|Smiles: [Mg+2].{{NAT} web|{NAT} Metabolic Enzyme/Protease|{NAT} Technical Information|{NAT} In Vitro|{NAT} custom synthesis|{NAT} Epigenetic Reader Domain} CC1=CN=C(C[S@](=O)C2[N-]C3=CC=C(C=C3N=2)OC)C(C)=C1OC.PMID:24563649 CC1=CN=C(C[S@@](=O)C2[N-]C3=CC=C(C=C3N=2)OC)C(C)=C1OC|InChiKey: KWORUUGOSLYAGD-FHPCUDFMSA-N|InChi: InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2/t2*24-;/m10./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.Products are for research use only. Not for human use.|